BioNJ Announces Lineup for BioPartnering Conference

TRENTON, N.J., April 25, 2024 /PRNewswire/ — BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City. Sponsored by J.P. Morgan, Johnson & Johnson and Morgan Lewis and hosted by Jersey City Economic Development Corp., the Conference will bring together life sciences executives, investors, strategics, academic collaborators and business development professionals for 1-1 partnering, Industry Connections (office hours with large biopharma companies), exhibits, company pitch presentations, plenary sessions and lots of networking — including a closing networking reception. 

The action-packed schedule is designed to create meaningful opportunities, grow the ecosystem and bolster medical innovation. Timely plenary sessions will include:

Industry Overview: Key Trends & OutlookBioPartnering: Keys to Success for Biotech and Pharma PartnershipsHow Biopharma Companies are Using AI to Accelerate InnovationVenture Capital’s New Era: Dynamic Shifts and Future Trends 

And, featuring thought leaders, such as:

Tyler Bryk, Head of Artificial Intelligence, PTC TherapeuticsSamuele Butera, President, U.S. Pulmonary Hypertension & Retina, Johnson & Johnson & Board Member, BioNJKim Cato, MBA, Vice President, Information Technology, Thermo Fisher ScientificSteven M. Cohen, J.D., Partner, Morgan LewisAlma DeMetropolis, CFA, CPF, Managing Director, J.P. Morgan Asset & Wealth ManagementJersey City Mayor Steven FulopDavid Schwartz, J.D., Partner & Leader, Corporate & Business Transaction Practice, Morgan Lewis Jim Gunton, MBA, Managing Partner & Founder, Tech Council VenturesDon Hass, J.D., Vice President, Head, Genetic Medicine Business Development, Regeneron PharmaceuticalsJenna Hebert, Ph.D., Senior Venture Associate, RA CapitalPaul Hoffman, President, Liberty Science CenterSophie Jones, M.D., Managing Director, J.P. Morgan, Healthcare Investment Banking Alan Leeds, J.D., Partner & Co-Leader, Global Life Sciences Practice, Morgan Lewis Partner Nancy Ondovik, MBA, Pharm.D., Principal, New Company Creation, Johnson & JohnsonEmilio Ragosa, J.D., Managing Partner, DLA Piper Hal Stern, Vice President & Chief Information Officer, R&D, Johnson & Johnson Innovation MedicinePhil Tinmouth, MBA, Chief Business Officer, Mammoth Biosciences

In addition, attendees can schedule 10-minute appointments at the Industry Connections Desk offering one-on-one time with BD professionals from large biopharma companies, such as Ferring Pharmaceuticals, Johnson & Johnson, Merck & Co., Pfizer, Sanofi and Teva Pharmaceuticals.

“The BioPartnering Conference is the ideal chance to discover innovative companies for investment portfolios,” BioNJ President and CEO Debbie Hart noted. “We have more than 90 companies from the life sciences, biotech, healthcare and digital health sectors presenting new innovations and technologies. With the One-on-One Partnering System open, attendees can begin scheduling meetings to explore collaboration opportunities.”

Emerging companies that will be presenting include:

4M TherapeuticsAccelerated BiosciencesACON PharmaceuticalsAdiso TherapeuticsAGelity BiomechanicsAOA DxArrePathAscent BioAspargo LabsAvistone BiotechnologyBeneviraBioCentriqCanget BioTekpharmaCourageneDevaCellEnalare TherapeuticsEpiBoneFrontAim BiomedicinesHanimune TherapeuticsIktosIlluminare BiotechnologiesIntrommune TherapeuticsJubilant TherapeuticsKayoTheraLactiga USMerlin BiotechNanomediGeneNemaGen DiscoveriesNeuropathixNuraLogixPanavance TherapeuticsPartexPharmaNestRegenosineRicovr HealthcareRx BandzSen-Jam PharmaceuticalSentauriSentrimedSFA TherapeuticsSignum BiosciencesSkunkWorx BioSoligenixSomnia TherapeuticsSynthis TherapeuticsTaxis PharmaceuticalsTelomEye PharmaceuticalsThread BioscienceTorigenVaxine USAViCardia TherapeuticsVital Start HealthVuja De SciencesXenon OphthalmicsXiconic PharmaceuticalsZiphius

Early stage start-up pitches include:

6S PharmaAbonicsAddinex TechnologiesAdvent TherapeuticsAperture BioAzome TherapeuticsBioLattice OphthalmicsClinical TrialsDelphine DiagnosticsDimer HealthHongyi TherapeuticsHopeAIInaedisInnerstillInteguRx TherapeuticsKogniticKolateAI PharmaTechLumaCellMaterialize BioMechano TherapeuticsMonarch TherapeuticsNeoventechNeuroPairOLI TechnologiesOrbits OncologyPressionPrima InnovationsSciMar ONESynergy TherapeuticstenXclinicalTRIZ Bio PharmaVasowatchVITRUVIAEZena Therapeutics

Conference attendees will have the opportunity to meet with a wide variety of exhibitors showcasing valuable resources, products and services available to the BioNJ community, including:

Advant-EdgeAmicus TherapeuticsAscellaHealthAscendia PharmaceuticalsBioBridgesBOME PharmaCFGIDatasiteDLA PiperFedsproutGenVaultGrant ThorntonJersey City Economic Development Corp.Johnson & JohnsonJ.P. MorganMarcumMiddlesex CountyMorgan LewisNJ Commission on Science, Innovation & TechnologyNJ Israel CommissionNJ Economic Development AuthorityNJ Health FoundationPrinceton BioLabsThermo FisherWithum

“We look forward to welcoming BioNJ’s preeminent 2024 BioPartnering Conference to the Liberty Science Center and introducing attendees to SciTech Scity, the 30-acre innovation campus we are now building that will focus on biomedical science, home healthcare, planet care and artificial intelligence,” said Paul Hoffman, President and CEO, Liberty Science Center and SciTech Scity. 

Register and find additional information at BioNJ.org/BioPartnering. Registration is $425 for BioNJ Members and $525 for Future BioNJ Members. Last year’s BioPartnering Conference brought together nearly 600 attendees from 16 states and 16 countries as well as the District of Columbia. 

Media Contact
Randi Bromberg
Sr. Vice President, Communications and Marketing
O) 609-890-3185
C) 609-955-1067
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/bionj-announces-lineup-for-biopartnering-conference-302127910.html

SOURCE BioNJ